Crystalys Therapeutics raises $130M Series B, led by Frazier Life Sciences, to bring gout drug dotinurad to US/EU markets. The drug is already approved in Japan, China.
James Mackay, Crystalys Therapeutics CEO
July 22, 2026 08:00 AM EDT
Crystalys gets $130M to take Sobi-rivaling gout drug to market
A San Diego biotech has raised an additional $130 million to get a gout drug that’s already approved in Japan and China onto the US …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Crystalys Therapeutics Announces $130 Million Series B Financing to Advance Global Phase 3 Development and Commercialization of Dotinurad for Gout
Crystalys nets $130M more to push gout drug through late-stage tests
Scribe Therapeutics surges 67% after $129M IPO as biotech market heats up
Crystalys Therapeutics Announces $130 Million Series B Financing to Advance Global Phase 3 Development and Commercialization of…
The startup has a broad global development program underway — and the support of more than 20 investment firms — for a treatment…
Sobi’s plan to introduce a challenger to Amgen’s blockbuster gout drug Krystexxa has been put on hold by the FDA. | Sobi’s plan…
Cyllene Therapeutics raised €33 million in a Series C and rebranded from EG 427 as it starts a potentially registrational Phase…
Claris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy for…
The FDA has issued Sobi, also known as Swedish Orphan Biovitrum, a complete response letter for its combination gout treatment…
